In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Biogen (BIIB – Research Report), with a price target of ...

In a report released yesterday, William Pickering from Bernstein maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

Shares of Biogen Inc. BIIB slipped 2.42% to $140.19 Wednesday, on what proved to be an all-around mixed trading session for ...

Even with the cheaper entry price, we're cautious about Biogen. Here are three reasons why BIIB doesn't excite us and a stock we'd rather own. Founded in 1978 in Switzerland as one of the first ...

The stock's fall snapped a seven-day winning streak.

2025 Non-GAAP Diluted EPS Guidance: Between $15.25 and $16.25. Biogen Inc (NASDAQ:BIIB) launched four first-in-class, disease-modifying products in Alzheimer's, Friedreich's ataxia, depression ...

Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Earnings Yield Investor model based on the published strategy of ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the April 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB ...

High-rolling investors have positioned themselves bullish on Biogen BIIB, and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking ...

Shares of BIIB opened at $150.38 on Friday. The company has a market capitalization of $22.01 billion, a P/E ratio of 13.44, a P/E/G ratio of 1.51 and a beta of 0.01. Biogen Inc. has a one year ...

Biogen (BIIB) Q4 2024 Earnings Call Transcript Story by Motley Fool Transcribing • 16m Biogen (NASDAQ: BIIB) Q4 2024 Earnings Call Feb 12, 2025, 8:30 a.m. ET ...